EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Selective phosphoinositide 3-kinase inhibitors and implication in diabetic retinopathy as pharmacological tools

Carmela Bonaccorso, Francesca Lazzara, Isabel La Rosa, Cristina Munzone, Alessandro Grasso, Chiara B M Platania, Claudio Bucolo

Frontiers in Pharmacology · 13.03.2026 · 17

DOI: 10.3389/fphar.2026.1744181 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.03.2026. Verfasst von Carmela Bonaccorso und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Sciences, University of Catania, Catania, Italy. Die Arbeit nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phosphoinositide 3-kinases (PI3Ks) are ubiquitous enzymes, that regulate different cellular functions, most involved in pathogenesis and progression of several oncological diseases. Indeed, some PI3K inhibitors have been approved for blood cancers, such as lymphoma. Interestingly, leniolisib, a selective PI3Kδ kinase inhibitor, has been approved for the rare disease Activated Phosphoinositide 3-kinase Delta Syndrome (APDS). Activation of PI3K/AKT signaling is downstream to VEGF-A pro-angiogenic signaling, detrimental in diabetic retinopathy progression, a microvascular complication of diabetes mellitus. Recently, a report evidenced that inhibition of class IA PI3K (PI3Kδ) delivered beneficial effects in an in-vivo model of diabetic retinopathy. We hereby explored the implication of PI3K signaling in diabetic retinopathy. Moreover, we reviewed the current literature to highlight molecular features of class I PI3K selective inhibitors, to further guide the design of novel selective and safe drugs targeting PI3Kδ, for management of diabetic retinopathy or other retinal proliferative diseases.

Schlagwörter

Stichwörter der Autor:innen

PI3K inhibitordiabetic retinopathyquantitative structure activity relationship (QSAR)repurposingretina

Autor:innen und Institutionen

  • Department of Chemical Sciences, University of Catania, Catania, Italy.
  • Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
  • Center for Research in Ocular Pharmacology-CERFO, University of Catania, Catania, Italy.
  • Department of Medicine and Surgery, "Kore" University of Enna, Enna, Italy.

Zitieren

APA

Bonaccorso, C., Lazzara, F., La Rosa, I., Munzone, C., Grasso, A., Platania, C. B. M., & Bucolo, C. (2026). Selective phosphoinositide 3-kinase inhibitors and implication in diabetic retinopathy as pharmacological tools. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1744181

Vancouver

Bonaccorso C, Lazzara F, La Rosa I, Munzone C, Grasso A, Platania CBM, et al. Selective phosphoinositide 3-kinase inhibitors and implication in diabetic retinopathy as pharmacological tools. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1744181

BibTeX
@article{Bonaccorso2026,
  author = {Bonaccorso, Carmela and Lazzara, Francesca and La Rosa, Isabel and Munzone, Cristina and Grasso, Alessandro and Platania, Chiara B M and Bucolo, Claudio},
  title = {Selective phosphoinositide 3-kinase inhibitors and implication in diabetic retinopathy as pharmacological tools},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1744181}
}
Kostenlos starten →